AMFENAC SODIUM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H12NO3.Na.H2O
Molecular Weight	295.2657
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.[Na+].NC1=C(CC([O-])=O)C=CC=C1C(=O)C2=CC=CC=C2

InChI

InChIKey=QZNJPJDUBTYMRS-UHFFFAOYSA-M

InChI=1S/C15H13NO3.Na.H2O/c16-14-11(9-13(17)18)7-4-8-12(14)15(19)10-5-2-1-3-6-10;;/h1-8H,9,16H2,(H,17,18);;1H2/q;+1;/p-1

HIDE SMILES / InChI

Molecular Formula	HO
Molecular Weight	17.0073
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C15H13NO3
Molecular Weight	255.2686
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB06802https://www.ncbi.nlm.nih.gov/pubmed/871089
Curator's Comment: Description was created based on several sources, including https://link.springer.com/article/10.1007/BF03299088 | http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=35377 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000MedR.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021862lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/10850857

Amfenac (AHR 5850) is a non-steroidal anti-inflammatory compound possessing antipyretic and analgesic properties. It is an inhibitor of cyclooxygenases. Amfenac sodium has been on the Japanese market since 1986 (as FENAZOX®, Meiji) in an oral dosage form (50 mg, four-times-daily) indicated for the treatment of pain and inflammation associated with rheumatoid and osteoarthritis and low back pain, as well as the treatment of pain and inflammation following surgery, injury or tooth extraction. Amfenac is an active moiety of nepafenac (amfenac amide), the prodrug has very weak cyclooxygenase inhibitory activity whereas amfenac exhibits more potent cyclooxygenase activity. Nepafenac at a concentration of 0.1% (NEVANAC) was approved for marketing in the US in 2005. Nepafenac is also approved for marketing in the European Union(EU) and Japan as well as over 60 other countries for the treatment of postoperative pain and inflammation associated with cataract surgery.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Cyclooxygenase-1 131 Target ID: CHEMBL221 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D05143	Inhibitor 8504	64.3 µM [IC50]
Cyclooxygenase-2 201 Target ID: CHEMBL230 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D05143	Inhibitor 8504	0.15 µM [IC50]
Cyclooxygenase-1 131 Target ID: CHEMBL221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10850857	Inhibitor 8504	0.25 µM [IC50]
Cyclooxygenase-2 201 Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10850857	Inhibitor 8504	0.15 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cataract 15 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021862s008lbl.pdf	Palliative		Approved 8583	NEVANAC Approved Use NEVANAC ophthalmic suspension is a nonsteroidal, antiinflammatory prodrug indicated for the treatment of pain and inflammation associated with cataract surgery Launch Date 2005
Pain 619 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=35377	Primary		Approved 8583	FENAZOX Approved Use FENAZOX CAPSULES (Amfenac sodium hydrate) is usually used to relieve inflammation and pain in chronic rheumatoid arthritis, osteoarthritis, low back pain, shoulder periarthritis, cervico-omo-brachial syndrome, temporomandibular joint disease, post-operative state, post-traumatic state or post-odontectomy state. Launch Date 1985

C_max

Value	Dose	Analyte	Population
5.62 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8376494/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	AMFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
70.1 ng/mL EXPERIMENT https://iovs.arvojournals.org/article.aspx?articleid=2383342	1 drop single, ocular dose: 1 drop route of administration: Ocular experiment type: SINGLE co-administered:	AMFENAC aqueous humor	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
205.3 ng/mL DRUG LABEL https://iovs.arvojournals.org/article.aspx?articleid=2383342	1 drop single, ocular dose: 1 drop route of administration: Ocular experiment type: SINGLE co-administered:	NEPAFENAC aqueous humor	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
0.847 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203491s001lbl.pdf	1 drop 1 times / day steady-state, ocular dose: 1 drop route of administration: Ocular experiment type: STEADY-STATE co-administered:	NEPAFENAC plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
0.921 ng/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf#page=12	1 drop single, ocular dose: 1 drop route of administration: Ocular experiment type: SINGLE co-administered:	NEPAFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
0.847 ng/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf#page=12	1 drop 1 times / day steady-state, ocular dose: 1 drop route of administration: Ocular experiment type: STEADY-STATE co-administered:	NEPAFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1.15 ng/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf#page=13	1 drop single, ocular dose: 1 drop route of administration: Ocular experiment type: SINGLE co-administered:	AMFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1.13 ng/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf#page=13	1 drop 1 times / day steady-state, ocular dose: 1 drop route of administration: Ocular experiment type: STEADY-STATE co-administered:	AMFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
6.11 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8376494/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	AMFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
178.1 ng × h/mL EXPERIMENT https://iovs.arvojournals.org/article.aspx?articleid=2383342	1 drop single, ocular dose: 1 drop route of administration: Ocular experiment type: SINGLE co-administered:	AMFENAC aqueous humor	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
331.1 ng × h/mL DRUG LABEL https://iovs.arvojournals.org/article.aspx?articleid=2383342	1 drop single, ocular dose: 1 drop route of administration: Ocular experiment type: SINGLE co-administered:	NEPAFENAC aqueous humor	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1.57 ng × h/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf#page=12	1 drop single, ocular dose: 1 drop route of administration: Ocular experiment type: SINGLE co-administered:	NEPAFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1.43 ng × h/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf#page=12	1 drop 1 times / day steady-state, ocular dose: 1 drop route of administration: Ocular experiment type: STEADY-STATE co-administered:	NEPAFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3.6 ng × h/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf#page=13	1 drop single, ocular dose: 1 drop route of administration: Ocular experiment type: SINGLE co-administered:	AMFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3.7 ng × h/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf#page=13	1 drop 1 times / day steady-state, ocular dose: 1 drop route of administration: Ocular experiment type: STEADY-STATE co-administered:	AMFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
1.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8376494/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	AMFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.85 h REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf#page=12	1 drop single, ocular dose: 1 drop route of administration: Ocular experiment type: SINGLE co-administered:	NEPAFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
0.74 h REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf#page=12	1 drop 1 times / day steady-state, ocular dose: 1 drop route of administration: Ocular experiment type: STEADY-STATE co-administered:	NEPAFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5.49 h REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf#page=13	1 drop single, ocular dose: 1 drop route of administration: Ocular experiment type: SINGLE co-administered:	AMFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6.26 h REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf#page=13	1 drop 1 times / day steady-state, ocular dose: 1 drop route of administration: Ocular experiment type: STEADY-STATE co-administered:	AMFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
1 drop 1 times / day multiple, topical Recommended Dose: 1 drop, 1 times / day Route: topical Route: multiple Dose: 1 drop, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24345529	unhealthy, 68.7+/- 9.08 Health Status: unhealthy Age Group: 68.7+/- 9.08 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/24345529	Disc. AE: Hypersensitivity... AEs leading to discontinuation/dose reduction: Hypersensitivity (0.12%) Sources: https://pubmed.ncbi.nlm.nih.gov/24345529
1 drop 1 times / day multiple, topical Recommended Dose: 1 drop, 1 times / day Route: topical Route: multiple Dose: 1 drop, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203491s001lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203491s001lbl.pdf	Disc. AE: Bleeding, Healing delayed... AEs leading to discontinuation/dose reduction: Bleeding Healing delayed Corneal disorder (NOS) Keratitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203491s001lbl.pdf
100 mg single, oral Studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3540874/	healthy Health Status: healthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/3540874/	Sources: https://pubmed.ncbi.nlm.nih.gov/3540874/

AEs

AE	Significance	Dose	Population
Hypersensitivity	0.12% Disc. AE	1 drop 1 times / day multiple, topical Recommended Dose: 1 drop, 1 times / day Route: topical Route: multiple Dose: 1 drop, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24345529	unhealthy, 68.7+/- 9.08 Health Status: unhealthy Age Group: 68.7+/- 9.08 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/24345529
Bleeding	Disc. AE	1 drop 1 times / day multiple, topical Recommended Dose: 1 drop, 1 times / day Route: topical Route: multiple Dose: 1 drop, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203491s001lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203491s001lbl.pdf
Corneal disorder (NOS)	Disc. AE	1 drop 1 times / day multiple, topical Recommended Dose: 1 drop, 1 times / day Route: topical Route: multiple Dose: 1 drop, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203491s001lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203491s001lbl.pdf
Healing delayed	Disc. AE	1 drop 1 times / day multiple, topical Recommended Dose: 1 drop, 1 times / day Route: topical Route: multiple Dose: 1 drop, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203491s001lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203491s001lbl.pdf
Keratitis	Disc. AE	1 drop 1 times / day multiple, topical Recommended Dose: 1 drop, 1 times / day Route: topical Route: multiple Dose: 1 drop, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203491s001lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203491s001lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2C19 2057 CYP2E1 1060 P-gp 1741	CYP 303 P-gp 2052 UGT enzymes 27

Drug as perpetrator

Target	Modality	Activity	Metabolite
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf Page: 14.0	inconclusive
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf Page: 14.0	inconclusive	amfenac 4
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf Page: 8, 14	no
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf Page: 8, 14	no	amfenac 4
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf Page: 8, 14	no
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf Page: 8, 14	no	amfenac 4
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf Page: 8, 14	no
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf Page: 8, 14	no	amfenac 4
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf Page: 8, 14	no
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf Page: 8, 14	no	amfenac 4
CYP2E1 1146	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf Page: 8, 14	no
CYP2E1 1146	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf Page: 8, 14	no	amfenac 4
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf Page: 8, 14	no
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf Page: 8, 14	no	amfenac 4

Drug as victim

Target	Modality	Activity	Metabolite
CYP 303	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf Page: 14.0	inconclusive	amfenac 4
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf Page: 14.0	inconclusive
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf Page: 14.0	inconclusive	amfenac 4
UGT enzymes 27	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf Page: 14.0	likely
UGT enzymes 27	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf Page: 14.0	likely	amfenac 4

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:75922	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:75922
ChemicalBook	CB01116872	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB01116872
eMolecules	10510502	https://www.emolecules.com/cgi-bin/more?vid=10510502
MolPort	MolPort-003-987-236	https://www.molport.com/shop/molecule-link/MolPort-003-987-236
Selleck Chemicals	Nepafenac	http://www.selleckchem.com/products/Nepafenac.html
ZINC	ZINC000005162311	http://zinc15.docking.org/substances/ZINC000005162311

PubMed

Title	Date	PubMed
Nepafenac: an ophthalmic nonsteroidal antiinflammatory drug for pain after cataract surgery.	2013-06	23715071
Effect of preoperative use of topical prednisolone acetate, ketorolac tromethamine, nepafenac and placebo, on the maintenance of intraoperative mydriasis during cataract surgery: a randomized trial.	2012-07	22824596
Ocular pharmacokinetics of 0.45% ketorolac tromethamine.	2010-12-01	21179226
Use of nepafenac (Nevanac) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections.	2010-10-28	21151329
Nepafenac-assisted mydriasis in a rabbit model.	2010-10	20674259
Comparison of three strains of diabetic rats with respect to the rate at which retinopathy and tactile allodynia develop.	2010-08-15	20806092
Topical nepafenac for treatment of exudative age-related macular degeneration.	2010-03	19364332
The effects of nepafenac and amfenac on retinal angiogenesis.	2010-02-15	19897019
NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema.	2010-02	20175270
Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema.	2010-01	19229275
Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications.	2010	20871825
Diabetic cataract-pathogenesis, epidemiology and treatment.	2010	20634936
Increased neuronal nitric oxide synthase activity in retinal neurons in early diabetic retinopathy.	2009-11-09	19936028
Differential effects of non-steroidal anti-inflammatory drugs on mitochondrial dysfunction during oxidative stress.	2009-10-01	19810214
Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%.	2009-10	19934822
Nepafenac-associated bilateral corneal melt after photorefractive keratectomy.	2009-09	19654513
Nepafenac: new drug. After cataract surgery: just another NSAID eye drop. No better than other NSAID eye drops, and less convenient to use.	2009-08	19743570
Nepafenac dosing frequency for ocular pain and inflammation associated with cataract surgery.	2009-08	19552601
Gateways to clinical trials.	2009-04	19536362
Etiology and treatment of the inflammatory causes of cystoid macular edema.	2009	22096351
Intracameral dexamethasone reduces inflammation on the first postoperative day after cataract surgery in eyes with and without glaucoma.	2009	19668589
Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac.	2009	19668569
Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution.	2009	19668566
Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%.	2009	19668559
Topical nepafenac in the treatment of diabetic macular edema.	2008-12	19668417
Nepafenac dosing frequency for ocular pain and inflammation associated with cataract surgery.	2008-12	19040348
Effect of nepafenac sodium 0.1% on delayed corneal epithelial healing and haze after photorefractive keratectomy: retrospective comparative study.	2008-09	18721717
Re: Pharmacokinetics and pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac.	2008-08	18655957
Topical nepafenac as an alternate treatment for cystoid macular edema in steroid responsive patients.	2008-07-31	18664937
Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension.	2008-06	19668727
Topical ocular delivery of NSAIDs.	2008-06	18437583
Amfenac increases the radiosensitivity of uveal melanoma cell lines.	2008-05	18049486
Effects of topical nepafenac on corneal epithelial healing time and postoperative pain after PRK: a bilateral, prospective, randomized, masked trial.	2008-04	18500088
Double-masked comparison of ketorolac tromethamine 0.4% versus nepafenac sodium 0.1% for postoperative healing rates and pain control in eyes undergoing surface ablation.	2008-04	18362679
Double-masked comparison of ketorolac tromethamine 0.4% versus nepafenac sodium 0.1% for postoperative healing rates and pain control in eyes undergoing surface ablation.	2008-04	18362678
Corneal melting after use of nepafenac in a patient with chronic cystoid macular edema after cataract surgery.	2008-03	18327052
Ketorolac versus nepafenac in cataract surgery.	2008-03	18299048
Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK).	2008-01-01	18165210
Analgesic and anti-inflammatory effectiveness of nepafenac 0.1% for cataract surgery.	2007-12	19668532
Re: Prostaglandin E(2) inhibition and aqueous concentration of ketorolac 0.4% and nepafenac 0.1% in patients undergoing phacoemulsification.	2007-12	18036883
Cystoid and diabetic macular edema treated with nepafenac 0.1%.	2007-12	18001248
The effects of a cyclooxygenase-2 (COX-2) expression and inhibition on human uveal melanoma cell proliferation and macrophage nitric oxide production.	2007-11-27	18042295
Nepafenac-associated corneal melt.	2007-11	17964407
Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trial.	2007-11	17964399
Double-masked study of the effects of nepafenac 0.1% and ketorolac 0.4% on corneal epithelial wound healing and pain after photorefractive keratectomy.	2007-09-29	17901034
Case of corneal melting associated with the use of topical nepafenac.	2007-09	17721306
Incidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenac.	2007-09	17720068
In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac.	2007-09	17720067
Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (acular LS) and nepafenac 0.1% (nevanac) in patients undergoing phacoemulsification.	2007-07	17601444
Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy.	2007	18274606

Patents

Sample Use Guides

In Vivo Use Guide

One drop of Nepafenac ophthalmic suspension, 0.3% should be applied to the affected eye one-time-daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period. An additional drop should be administered 30 to 120 minutes prior to surgery.

Route of Administration: Topical

In Vitro Use Guide

Nepafenac exhibited only weak COX-1 inhibitory activity (IC50 = 64.3 uM). However, amfenac, an active metabolite of nepafenac, was a potent inhibitor of COX-1 (IC50 = 0.25 uM) and COX-2 activity (IC50 = 0.15 uM).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:39:18 GMT 2025` Edited by `admin` on `Mon Mar 31 18:39:18 GMT 2025`
Record UNII	PPF9V8J28Y
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AMFENAC SODIUM

Official Name

English

FENAZOX

Preferred Name

English

AMFENAC SODIUM [USAN]

Common Name

English

AHR-5850D

Code

English

AMFENAC SODIUM SALT MONOHYDRATE

Common Name

English

AMFENAC SODIUM SALT MONOHYDRATE [MI]

Common Name

English

AMFENAC SODIUM HYDRATE [JAN]

Common Name

English

Sodium (2-amino-3-benzoylphenyl)acetate monohydrate

Systematic Name

English

AMFENAC SODIUM [MART.]

Common Name

English

BENZENEACETIC ACID, 2-AMINO-3-BENZOYL-, SODIUM SALT, MONOHYDRATE

Common Name

English

AMFENAC SODIUM HYDRATE

Common Name

English

SODIUM AMFENAC

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C257